OrbiMed is a long-term healthcare fund, and this incremental sale appears to be routine portfolio management. Monitor for any actual selling via Form 4 filings, but this 144 notice alone is not actionable.
Price Chart
Executive Summary
OrbiMed Advisors LLC filed a Form 144 notice of intent to sell 26,323 shares of Enliven Therapeutics (ELVN), held by its managed fund OrbiMed Genesis Master Fund, L.P. This represents a routine partial sale by a major healthcare-focused institutional insider, not by company executives. At a ~$2.7B market cap and with robust analyst sentiment, this filing is low impact.
Key Facts
- OrbiMed Advisors LLC filed a Form 144 for the proposed sale of 26,323 shares of ELVN common stock.
- The selling entity is OrbiMed Genesis Master Fund, L.P., an investment fund managed by OrbiMed Advisors, not an executive or director.
- The total proposed sale value is approximately $1.14M based on filing date prices, a fraction of OrbiMed's overall ELVN stake.
- The shares were acquired via merger on 02/23/2023 (when Enliven was IMARA Inc.) and have been held since.
- A small prior sale of 9,086 shares occurred on 06/15/2026 (~$409K).
Financial Impact
Proposed sale of ~$1.14M at ~$2.7B market cap (0.04% of market cap, trivial dilution signal).
Risk Factors
- Insider selling could continue if OrbiMed's conviction diminishes, but no current sign of that.
- No company-specific or clinical catalyst is indicated alongside this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0000947871-26-000650 |
| Document: 0000947871-26-000650-index.html | 0000947871-26-000650 |
| Document: 0000947871-26-000650.txt | 0000947871-26-000650 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | Insider Cluster | $41.93 | awaiting T+5 | — | $41.49 (−1.05%) |
Oct 19, 2026 7d ago | 144 | $41.25 | awaiting T+5 | — | $41.49 (+0.58%) |
Oct 16, 2026 10d ago | 3 | $38.70 $41.49 | ▲ +7.21% | ▲ +7.35% | $41.49 (+7.21%) |
Oct 14, 2026 12d ago | 8-K | $39.33 $41.93 | ▲ +6.61% | ▲ +7.63% | $41.49 (+5.49%) |
Sep 21, 2026 5w ago | Insider Cluster | $48.19 $46.51 | ▼ −3.49% | ▼ −2.30% | $41.49 (−13.90%) |
Sep 4, 2026 7w ago | 144 | $59.32 $54.43 | ▼ −8.24% | ▼ −7.03% | $41.49 (−30.06%) |
Aug 19, 2026 9w ago | Insider Cluster | $58.97 $60.50 | ▲ +2.59% | ▲ +1.48% | $41.49 (−29.64%) |
Aug 9, 2026 11w ago | Institutional Cluster | $59.42 $59.54 | ▲ +0.19% | ▲ +0.24% | $41.49 (−30.18%) |
Jul 21, 2026 13w ago | Insider Cluster | $52.85 $52.97 | ▲ +0.23% | ▲ +2.63% | $41.49 (−21.49%) |
Jun 22, 2026 17w ago | 144 | $48.60 $50.85 | ▲ +4.63% | ▲ +3.62% | $41.49 (−14.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers